Navigation Links
Cancer treatments in phase 3 trials successful up to half of the time

CHICAGO About one-fourth to one-half of new cancer treatments that reach assessment in phase 3 randomized clinical trials are eventually proven successful, according to a report in the March 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Cancer remains the second leading cause of death in the United States, but continuous improvements have been made in survival and other outcomes, according to background information in the article. To a large extent, this has occurred through the introduction of new treatments tested in clinical trials, with randomized controlled trials (RCTs) widely considered to be the most reliable method of assessing differences between the effects of health care interventions, the authors write. Cancer is the only disease for which the National Institutes of Health has consistently funded a cooperative clinical trial infrastructure. Despite this investment, little is known about the proportion of clinical trials that have led to the discovery of successful new treatments.

Benjamin Djulbegovic, M.D., Ph.D., of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, and colleagues extracted data from all completed phase 3 randomized clinical trials conducted by the National Cancer Institute cooperative groups since their inception in 1955. A total of 624 trials involving 216,451 patients were analyzed.

Overall, 30 percent of the trials had statistically significant results; in 80 percent of those cases, new treatments were superior to established protocols. The original researchers reported that the risk-benefit ratio favored new treatments in 41 percent of comparisons, while standard treatments were favored in 59 percent of comparisons.

The real effects of new treatments compared with standard treatments in terms of patient outcomes such as survival is best measured by quantitative pooling of data, the authors write. When done this way, new treatments are, on average, found to be slightly superior to standard treatments, with a 5 percent relative reduction in the death rate. This, of course, should not be understood as the average effects of new discoveries being equally spread among all patients. In 15 percent of the trials, breakthrough therapies were discovered; in 2 percent of the cases, these reduced the death rate by more than 50 percent.

In conclusion, society has received a good return on its investment in the cooperative oncology group system, which funds the trials, the authors write. The public can expect that about 25 percent to 50 percent of new cancer treatments that reach the stage of assessment in randomized clinical trials will prove to be successful. This pattern of successes has become more consistent over time. However, our results also indicate that the absolute number of discoveries might be improved if the proportion of inconclusive trials is reduced.


Contact: Nancy Johnson
JAMA and Archives Journals

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... ... recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: